I think it’s Ok. Revenue nearly to cashburn per quarter, within...

I think it’s Ok.

Revenue nearly to cashburn per quarter, within 10% by Q3 . However— private payor success is happening!

And SOZO once installed becomes of course indispensable to centres using for their patients , and how could they go back to tape measuring for post- cancer lymphodema monitoring for their patients.
It’s obscene to not continue using SOZO when it is so crucial to detect lymphodema early in order to manage and actually prevent permanent debilitation occuring.

Cancer treatment centres with SOZO now would scarcely consider not utilising the correct fluid analysis if can best screen for sarcopenia prior to chemotherapy in vulnerable patients.




And NCCN result in the next few months- this quarter.

How can this not be standard of care for lymphodema monitoring & detection, as well as best management during and post - cancer treatment.